• +1-646-491-9876
    • +91-20-67278686

    Search

    Benign Prostatic Hyperplasia-Pipeline Review H1 2017

    Benign Prostatic Hyperplasia-Pipeline Review H1 2017

    • Report Code ID: RW0001834328
    • Category Pharmaceuticals
    • No. of Pages 113
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Benign Prostatic Hyperplasia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

    Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 6, 3, 1, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

    Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health) .
    - The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Benign Prostatic Hyperplasia - Overview
    Benign Prostatic Hyperplasia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Benign Prostatic Hyperplasia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
    Addex Therapeutics Ltd
    AndroScience Corp
    Aphios Corp
    BCWorld Pharm Co Ltd
    Biolab Farmaceutica Ltda
    Chong Kun Dang Pharmaceutical Corp
    Curadis GmbH
    Dongkook Pharmaceutical Co Ltd
    GL Pharm Tech Corp
    Hanmi Pharmaceuticals Co Ltd
    Health Ever Bio-Tech Co Ltd
    Jeil Pharmaceutical Co Ltd
    Kaken Pharmaceutical Co Ltd
    MEI Pharma Inc
    Meiji Seika Pharma Co Ltd
    Mezzion Pharma Co Ltd
    Monosol Rx LLC
    Nymox Pharmaceutical Corp
    Ono Pharmaceutical Co Ltd
    OPKO Health Inc
    SK Chemicals Co Ltd
    SOM Biotech SL
    Sophiris Bio Inc
    Vantia Therapeutics
    XuanZhu Pharma Co Ltd
    Yungjin Pharm Co Ltd
    Benign Prostatic Hyperplasia - Drug Profiles
    (dutasteride + tadalafil) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (tadalafil + tamsulosin hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (tadalafil + tamsulosin hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ADX-68692 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASC-JM.X2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AUS-131 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BCWPE-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BL-214 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CR-1447 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fadanafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fedovapagon - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fexapotide triflutate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KKM-1202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-1AD3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MCS-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NCE-403 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ONO-8430506 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-0131632 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-40542 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SOM-2391 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SOM-2393 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sperol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tadalafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    talaporfin sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tamsulosin hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tamsulosin hydrochloride DR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tamsulosin hydrochloride SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tertomotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    topsalysin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TT-701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    udenafil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YBH-1603 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YOB-1604 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Benign Prostatic Hyperplasia - Dormant Projects
    Benign Prostatic Hyperplasia - Discontinued Products
    Benign Prostatic Hyperplasia - Product Development Milestones
    Featured News & Press Releases
    May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe
    May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
    Mar 29, 2017: Nymox Provides Update on Fexapotide Development
    Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug - Fadanafil
    Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
    Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692
    May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
    Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
    Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
    Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
    Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
    Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
    Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
    Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
    Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Monosol Rx LLC, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Vantia Therapeutics, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H1 2017
    Benign Prostatic Hyperplasia - Dormant Projects, H1 2017
    Benign Prostatic Hyperplasia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Benign Prostatic Hyperplasia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Addex Therapeutics Ltd
    AndroScience Corp
    Aphios Corp
    BCWorld Pharm Co Ltd
    Biolab Farmaceutica Ltda
    Chong Kun Dang Pharmaceutical Corp
    Curadis GmbH
    Dongkook Pharmaceutical Co Ltd
    GL Pharm Tech Corp
    Hanmi Pharmaceuticals Co Ltd
    Health Ever Bio-Tech Co Ltd
    Jeil Pharmaceutical Co Ltd
    Kaken Pharmaceutical Co Ltd
    MEI Pharma Inc
    Meiji Seika Pharma Co Ltd
    Mezzion Pharma Co Ltd
    Monosol Rx LLC
    Nymox Pharmaceutical Corp
    Ono Pharmaceutical Co Ltd
    OPKO Health Inc
    SK Chemicals Co Ltd
    SOM Biotech SL
    Sophiris Bio Inc
    Vantia Therapeutics
    XuanZhu Pharma Co Ltd
    Yungjin Pharm Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//benign-prostatic-hyperplasia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//benign-prostatic-hyperplasia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//benign-prostatic-hyperplasia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments